Full Description
The introduction of tumor-necrosis-factor-alpha (TNFa) blocking agents is one of the milestones in the therapy of rheumatoid arthritis (RA). Edited by Larry Moreland and Paul Emery, experts in rheumatological disease, TNFa-Inhibition in the Treatment of Rheumatoid Arthritis charts the history and development of the concept of TNFa inhibition. The authors document TNFa from its discovery to its now well-documented clinical applications in the treatment of patients with RA. They compare and contrast practical management issues concerning the use of these agents both in the US and UK/Europe. The book is a practical and accessible source containing the most recent information in this field.
Contents
Definition of TNFa as a Therapeutic Target for Rheumatoid Arthritis, M. Feldman, F.M. Brennan, R.O. Williams, and R.N. MainiInfliximab Therapy, R.N. Maini and M. FeldmanEtanercept, S.Sule and J.M. BathanAdalimumab, L. van de Putte, J. Salfeld, and S. Kaymakcalanp-55 TNF Receptor Therapy, J.J. CashTNFa-Inhibition in Practical Management of Rheumatoid Arthritis: The US Model, J.C. Shanahan and L.W. MorelandTNFa-inhibition in Practical Management: The UK/European Model, P. EmerySafety Issues with Anti-TNF Agents: Immunomodulation and Infection, J.C. ShanahanIndex
